Literature DB >> 9294687

Immunolocalization of bFGF in pterygia: association with mast cells.

M R Powers1, Z Qu, B O'Brien, D J Wilson, J E Thompson, J T Rosenbaum.   

Abstract

PURPOSE: To examine the expression of basic fibroblast growth factor in pterygia and determine whether mast cells contain basic fibroblast growth factor (bFGF) in this disease process.
METHODS: Formalin-fixed paraffin-embedded tissue samples of pterygia (n = 14) were used to study the expression of bFGF with immunohistochemistry. Seven samples were also double labeled with specific antibodies to bFGF and tryptase (a specific mast cell marker).
RESULTS: In all tissue samples examined, bFGF was specifically localized in blood vessels, epithelium, and a subset of connective tissue cells. The majority of bFGF-positive connective tissue cells were also tryptase positive (90.4 +/- 3.6%). Nearly all the tryptase-positive cells (mast cells) in the pterygia tissues coexpressed bFGF (98 +/- 1.5%).
CONCLUSIONS: These findings suggest that bFGF may have biologic effects on the epithelium and blood vessels in pterygia, with epithelial and endothelial cells as a possible source. In addition, mast cells contain bFGF in the pterygia tissues examined in this study. The mast cells may serve as an additional source of bFGF, possibly modulating a variety of cell types as well as the extracellular matrix in pterygia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294687

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  9 in total

Review 1.  Ocular mast cells. Characterization in normal and disease states.

Authors:  E B Cook; J L Stahl; N P Barney; F M Graziano
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

2.  The role of ultraviolet irradiation and heparin-binding epidermal growth factor-like growth factor in the pathogenesis of pterygium.

Authors:  Timothy M Nolan; Nick DiGirolamo; Nitin H Sachdev; Taline Hampartzoumian; Minas T Coroneo; Denis Wakefield
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

3.  Topical dobesilate eye drops for ophthalmic primary pterygium.

Authors:  Pedro Cuevas; Luis A Outeiriño; Javier Angulo; Guillermo Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2012-03-08

Review 4.  Aberrant expression of genes and proteins in pterygium and their implications in the pathogenesis.

Authors:  Qing-Yang Feng; Zi-Xuan Hu; Xi-Ling Song; Hong-Wei Pan
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

5.  The Key Role of VEGF in the Cross Talk between Pterygium and Dry Eye and Its Clinical Significance.

Authors:  Chang Liu; Yiyue Song; Xiaoran Wang; Zhaoguang Lai; Chaoyang Li; Pengxia Wan; Nuo Xu; Danping Huang; Yizhi Liu; Zhichong Wang
Journal:  Ophthalmic Res       Date:  2020-01-10       Impact factor: 2.892

6.  Distribution of extracellular matrix proteins in pterygia: an immunohistochemical study.

Authors:  Wallid Naib-Majani; Isam Eltohami; Nicolas Wernert; William Watts; Harald Tschesche; Uwe Pleyer; Winrich Breipohl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-01-29       Impact factor: 3.117

7.  Efficacy of curcumin in inducing apoptosis and inhibiting the expression of VEGF in human pterygium fibroblasts.

Authors:  Cheng-Wei Lu; Ji-Long Hao; Lei Yao; Hai-Jun Li; Dan-Dan Zhou
Journal:  Int J Mol Med       Date:  2017-04-07       Impact factor: 4.101

8.  Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage.

Authors:  Bing Wang; Pui-Kai Li; Jian-Xing Ma; Danyang Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-07-02       Impact factor: 4.799

9.  Neovascularization and mast cells with tryptase activity increase simultaneously in human pterygium.

Authors:  Domenico Ribatti; Beatrice Nico; Cristina Maxia; Vito Longo; Daniela Murtas; Domenica Mangieri; M Teresa Perra; Michela De Giorgis; Franca Piras; Enrico Crivellato; Paola Sirigu
Journal:  J Cell Mol Med       Date:  2007 May-Jun       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.